NASDAQ:HOOK HOOKIPA Pharma (HOOK) Stock Price, News & Analysis $0.88 +0.04 (+4.78%) As of 08/8/2025 03:47 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About HOOKIPA Pharma Stock (NASDAQ:HOOK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HOOKIPA Pharma alerts:Sign Up Key Stats Today's Range$0.81▼$0.9450-Day Range$0.84▼$1.5852-Week Range$0.72▼$5.66Volume147,712 shsAverage Volume188,481 shsMarket Capitalization$10.73 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingHold Company Overview HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York. Read More HOOKIPA Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreHOOK MarketRank™: HOOKIPA Pharma scored higher than 57% of companies evaluated by MarketBeat, and ranked 431st out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingHOOKIPA Pharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageHOOKIPA Pharma has received no research coverage in the past 90 days.Read more about HOOKIPA Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for HOOKIPA Pharma are expected to decrease in the coming year, from ($1.75) to ($2.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of HOOKIPA Pharma is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HOOKIPA Pharma is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHOOKIPA Pharma has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about HOOKIPA Pharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.51% of the float of HOOKIPA Pharma has been sold short.Short Interest Ratio / Days to CoverHOOKIPA Pharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in HOOKIPA Pharma has recently decreased by 67.54%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHOOKIPA Pharma does not currently pay a dividend.Dividend GrowthHOOKIPA Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.51% of the float of HOOKIPA Pharma has been sold short.Short Interest Ratio / Days to CoverHOOKIPA Pharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in HOOKIPA Pharma has recently decreased by 67.54%, indicating that investor sentiment is improving significantly. News and Social Media1.1 / 5News SentimentN/A Search Interest1 people have searched for HOOK on MarketBeat in the last 30 days. MarketBeat Follows2 people have added HOOKIPA Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, HOOKIPA Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $39,362.00 in company stock.Percentage Held by InsidersOnly 3.30% of the stock of HOOKIPA Pharma is held by insiders.Percentage Held by Institutions63.88% of the stock of HOOKIPA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about HOOKIPA Pharma's insider trading history. Receive HOOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HOOKIPA Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address HOOK Stock News HeadlinesHOOKIPA Pharma Inc. (NASDAQ:HOOK) CFO Mary Theresa Coelho Sells 13,609 SharesJuly 24, 2025 | insidertrades.comHOOKIPA Pharma Inc. Announces Intent to Voluntarily Delist from Nasdaq and Pursue Asset Sale with Gilead SciencesJuly 18, 2025 | quiverquant.comQMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.August 9 at 2:00 AM | American Alternative (Ad)HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common StockJuly 18, 2025 | globenewswire.comHookipa Pharma Inc News (HOOK) - Investing.comJune 24, 2025 | investing.comGilead (GILD) to Acquire HOOK for $10 millionMay 23, 2025 | msn.comGilead to buy certain Hookipa Pharma assets for up to $10MMay 22, 2025 | msn.comHookipa Pharma (HOOK) Receives a Hold from RBC CapitalMarch 4, 2025 | markets.businessinsider.comSee More Headlines HOOK Stock Analysis - Frequently Asked Questions How have HOOK shares performed this year? HOOKIPA Pharma's stock was trading at $2.01 on January 1st, 2025. Since then, HOOK stock has decreased by 56.2% and is now trading at $0.8805. How were HOOKIPA Pharma's earnings last quarter? HOOKIPA Pharma Inc. (NASDAQ:HOOK) released its quarterly earnings data on Thursday, May, 15th. The company reported ($1.23) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by $0.62. HOOKIPA Pharma had a negative trailing twelve-month return on equity of 120.09% and a negative net margin of 785.66%. When did HOOKIPA Pharma's stock split? HOOKIPA Pharma shares reverse split on the morning of Wednesday, July 10th 2024.The 1-10 reverse split was announced on Wednesday, July 10th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did HOOKIPA Pharma IPO? HOOKIPA Pharma (HOOK) raised $100 million in an initial public offering (IPO) on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Kempen was co-manager. How do I buy shares of HOOKIPA Pharma? Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of HOOKIPA Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that HOOKIPA Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Pfizer (PFE), Advanced Micro Devices (AMD), Cabaletta Bio (CABA) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings5/15/2025Today8/09/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HOOK CIK1760542 Webwww.hookipapharma.com Phone431-890-6360Fax43-1890-636-0399Employees160Year FoundedN/APrice Target and Rating Average Price Target for HOOKIPA Pharma$4.50 High Price Target$7.00 Low Price Target$2.00 Potential Upside/Downside+411.1%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($5.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.50 million Net Margins-785.66% Pretax Margin-785.15% Return on Equity-120.09% Return on Assets-77.14% Debt Debt-to-Equity RatioN/A Current Ratio3.61 Quick Ratio3.61 Sales & Book Value Annual Sales$43.95 million Price / Sales0.24 Cash FlowN/A Price / Cash FlowN/A Book Value$4.25 per share Price / Book0.21Miscellaneous Outstanding Shares12,190,000Free Float11,787,000Market Cap$10.73 million OptionableOptionable Beta0.93 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:HOOK) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HOOKIPA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HOOKIPA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.